Dogwood Therapeutics, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Dogwood Therapeutics entered a subscription agreement on October 19, 2026 with CK Life Sciences International (Holdings) Inc., a subsidiary, for $5,000,000 in a private placement. Dogwood will issue 4,098,360 shares of common stock at $1.22 per share. Proceeds extend runway through March 2027 to fund Phase 3 preparatory activities for lead candidate Halneuron® ahead of November 2026 topline Phase 2b data readout.
Why this rating
Investment is ~62% of company market cap ($8.1M); funds 5+ months of operations and Phase 3 prep for lead program with near-term data catalyst. Meaningful capital infusion from existing major shareholder demonstrates confidence but not transformational.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.